A real-time quantitative RT-PCR assay for monitoring DEK-CAN fusion transcripts arising from translocation t(6;9) in acute myeloid leukemia.
We have developed a real-time quantitative RT-PCR (RQ-PCR) assay for the DEK-CAN fusion transcript, which results from t(6;9)(p23;q34) and is found in about 1% of acute myeloid leukemia (AML) cases. In diagnostic samples from three acute myeloid leukemia patients an RQ-PCR assay sensitivity of 1:396-1:3446 was obtained. In a single patient followed closely for 57 weeks, an increasing DEK-CAN level was detected 40 days before an early hematological relapse. This assay should enable the widespread longitudinal minimal residual disease (MRD) follow-up in this rare subgroup of AML patients, thus adding to our knowledge of its course.
Østergaard
Mette
M
Department of Hematology, Aarhus University Hospital, Tage-Hansens Gade 2, 8000 C, Denmark.
Stentoft
Jesper
J
Hokland
Peter
P
D000208:Acute Disease; D000818:Animals; D002896:Chromosomes, Human, Pair 6; D002899:Chromosomes, Human, Pair 9; D003561:Cytarabine / Q000008:administration & dosage / Q000494:pharmacology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics*; D006801:Humans; D007377:Interleukin-3 / Q000235:genetics*; D007951:Leukemia, Myeloid / Q000378:metabolism*; D051379:Mice; D016513:Mice, SCID; D015513:Oncogene Proteins / Q000008:administration & dosage / Q000235:genetics / Q000494:pharmacology*; D015514:Oncogene Proteins, Fusion; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014178:Translocation, Genetic
C104001:DEK-CAN fusion protein, recombinant; D007377:Interleukin-3; D015513:Oncogene Proteins; D015514:Oncogene Proteins, Fusion; D011993:Recombinant Fusion Proteins; D003561:Cytarabine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor